-
-
-
-
-
-
-
Neurocrine Bio. (NBIX) PT Raised to $185 at Morgan Stanley
-
-
-
-
-
-
-
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
-
-
-
-
-
-
-
Neurocrine Biosciences Announces CEO Succession Plan
-
-
-
-
-
-
-
Goldman Sachs Upgrades Neurocrine Bio. (NBIX) to Buy
-
-
-
-
-
-
-
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders
-
-
-
-
-
-
-
Pre-Open Stock Movers 05/24: (INO) (TCS) (TLYS) Higher; (ANW) (DY) (CHS) Lower (more...)
-
-
-
-
-
-
-
Today's Biotech Upside Could Be Just the Start - BMO Capital (IBB) (XBI)
-
1,154,895 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

